Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect

Kenta Yagi1 | Marin Mitstui2 | Yoshito Zamami2,3 | Takahiro Niimura2 | Yuki Izawa-Ishizawa4 | Mitsuhiro Goda3 | Masayuki Chuma1 | Kimiko Fukunaga2 | Takahiro Shibata3 | Shunsuke Ishida3 | Takumi Sakurada3 | Naoto Okada3 | Hiroki Yanagawa1 | Keisuke Ishizawa2,3

1Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan
2Department of Clinical Pharmacology and Therapeutics, University of Tokushima Graduate School of Biomedical Sciences, Tokushima, Japan
3Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan
4Department of Pharmacology, University of Tokushima Graduate School of Biomedical Sciences, Tokushima, Japan

Correspondence
Yoshito Zamami, Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan, 2-50-1 Kuramoto-cho, Tokushima 770-8503, Japan.
Email: zamami@tokushima-u.ac.jp

Funding information
This research was supported by the Japan Research Foundation for Clinical Pharmacology Grant (Grant number 2018A10) and the Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant number 18K06785)

Abstract

Background: In patients treated with bevacizumab, hypertension may be a biomarker of therapeutic efficacy. However, it is not clear whether drugs that control blood pressure influence bevacizumab’s efficacy. In this study, we investigated drugs that may affect hypertension in bevacizumab-treated patients and examined the impact on the therapeutic effect.

Patients and methods: We analyzed 3,724,555 reports from the third quarter of 2010 to the second quarter of 2015. All data were obtained from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) analysis. In this retrospective cohort study, we investigated a total of 58 patients diagnosed with colorectal cancer and treated for the first time with bevacizumab containing XELOX or mFOLFOX6 at The University of Tokushima Hospital between January 2010 and December 2015. The effect of the treatment was evaluated according to Response Evaluation Criteria in Solid Tumors version 1.0. Thereafter, the effect was confirmed using Gene Expression Omnibus (GEO) and cultured cells.

Results: There are few reports in FAERS of hypertension in patients treated with omeprazole on bevacizumab. Based on the chart review, patients who used proton pump inhibitors (PPI) had a lower response to treatment than those who did not (response rate: 25% vs 50%). Furthermore, experiments on GEO and cell lines suggested that induction of vascular endothelial growth factor (VEGF) gene expression by PPIs is the cause of the reduced therapeutic effect.

Conclusion: PPIs prevent hypertension in bevacizumab-treated patients but may reduce bevacizumab’s anti-tumoral effects by inducing VEGF expression.

Keywords
bevacizumab, colorectal cancer, FAERS, gene expression omnibus, hypertension, proton pump inhibitor
INTRODUCTION

Bevacizumab is a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF) that inhibits tumor growth by inhibiting angiogenesis. It has shown antitumor effects in several cancer types, including colorectal cancer, breast cancer, non-small cell lung cancer, renal cell carcinoma, ovarian cancer, glioblastoma, and metastatic melanoma.1-3 Bevacizumab has been used in combination with chemotherapy, and has been reported to prolong both overall survival and progression-free survival.4-6 However, bevacizumab causes a variety of adverse events, one of which is hypertension. One clinical study reported that after bevacizumab treatment, 49.3% of patients had induced-grade 2, or higher hypertension.3

Hypertension induced by bevacizumab administration is thought to occur due to decreased endothelial cell regenerative capacity and decreased production of vasodilators, such as nitric oxide and prostacyclin.7 VEGF inhibition leads to the reduction of nitric oxide synthesis, thus reducing the levels of nitric oxide in the body,7 which in turn leads to constriction of the blood vessels, and a reduction in sodium ion renal excretion, ultimately resulting in hypertension.8 The development of bevacizumab-induced hypertension is one of the most important problems in continuing the bevacizumab treatment, and even deaths have been reported due to the development of hypertension. If bevacizumab-induced hypertension develops, bevacizumab should be stopped immediately until blood pressure control is achieved.9-11

However, several retrospective studies have suggested that among patients treated with bevacizumab, those who developed hypertension had a better prognosis than those who did not.8,12-15 Indeed, in patients with metastatic colorectal cancer who received combination chemotherapy with bevacizumab, overall response, progression-free survival, and overall survival were associated with the emergence of hypertension.13 These studies suggest that the appearance of hypertension may be a biomarker of treatment efficacy in patients treated with bevacizumab. In addition, it is possible that drugs reducing the occurrence of hypertension in patients receiving bevacizumab might have a negative effect on the efficacy of bevacizumab treatment, however, their associations are currently not clear. Most patients treated with bevacizumab use several concomitant drugs. Among these concomitant drugs, there might be several drugs that could alter the blood pressure, but to the best of our knowledge, there are no studies on the interactions of these drug combinations. This could be probably explained partly by the fact that concomitant medications are so varied that it would be difficult to adequately study them in studies involving a small number of centers.

The Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) is the world’s largest database created by the U.S. FDA to monitor the safety risks of approved drugs. Adverse events related to drug use are voluntarily reported to FAERS by patients, physicians, pharmacists, and other health care providers. Currently, millions of drug-related adverse events are registered in FAERS, which in recent years has supported several academic studies on drug safety and development that are separate from the FDA’s objective of monitoring drug adverse events. For example, FAERS analysis has shown that concomitant drug B reduces the risk of adverse events caused by drug A.16,17 Additionally, the Gene Expression Omnibus (GEO) is a global data repository of next-generation sequencing, microarray, and high-throughput functional genomics data submitted by research communities.18 It is also an integrated database for systematic analyses of gene function and linking gene information with higher-order functional information.19 We have previously analyzed large information databases, such as FAERS and GEO to identify novel drug effects of existing drugs.20-22

These databases have enabled us to analyze the effects of concomitant drugs, and to estimate the mechanisms of their effects, which otherwise cannot be analyzed in a few centers due to the inadequate number of cases. Therefore, in this study, we aimed to investigate drugs that could alter the incidence of hypertension in bevacizumab-treated patients and examine whether these drugs could affect the treatment efficacy.

RESULTS

2.1 FAERS analysis for determining the relationship between bevacizumab and hypertension

The FAERS database was used to investigate the occurrence of hypertension in patients treated with bevacizumab. Of 36,95,466 patients, hypertension was reported in 85,079 patients and in 1,520 using bevacizumab. The reporting odds ratio (ROR) for bevacizumab use and hypertension was 2.45, 95% confidence interval (CI): 2.33-2.59, p < 0.001, which indicated a strong relationship. A similar relationship was found when the patients were stratified by sex and age (Table 1). Bevacizumab was found to be associated with an increased incidence of hypertension in FAERS, regardless of age or sex.

2.2 FAERS-based search for drugs reducing hypertension in patients treated with bevacizumab

The FAERS was used to identify concomitant drugs that were associated with a reduced incidence of hypertension in patients treated with bevacizumab. Epirubicin, Erlotinib, and
omeprazole were found to be associated with a lower rate of hypertension in patients treated with bevacizumab (Table 2) in the FAERS analysis. However, among them, patients using omeprazole reported the highest incidence of hypertension.

2.3  Demographic and clinical characteristics of patients by examining their medical records

Between January 2010 and December 2015, 62 patients from The Tokushima University Hospital were treated with bevacizumab in combination with XEROX or mFOLFOX6, among whom 58 were included in the analysis. Table 3 shows the patients’ characteristics in the PPI (n = 16) and non-PPI (n = 42) groups. There were no significant differences between the two groups regarding median age at diagnosis, sex, performance status (PS), histopathological staging, concomitant regimens, or concomitant antihypertensive medications (Table 3).

2.4  Influence of PPI-use on the effectiveness of chemotherapy, including bevacizumab

Response rates were measured. No patient had complete response (CR), 25 had partial response (PR), 24 had stable disease (SD), and 9 had progressive disease (PD). The response rate was 50% in the non-PPI group and 25% in the PPI group; objective response rate (ORR) was 25% higher in the non-PPI group than that in the PPI group, with no significant difference. The disease control rate was 50% in the non-PPI group and 25% in the PPI group. The disease control rate of the non-PPI group was 21% higher than the PPI group but not significant (Table 3).

2.5  Evaluating changes in signaling pathways and gene expression associated with the pathway of hypertension using the GEO and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases

To investigate the mechanism of effect of bevacizumab in patients using omeprazole, we analyzed a GEO-deposited toxicogenomics microarray dataset (GEO Association No. GSE59927). Using these data sets, we analyzed the differences in gene expression in rats treated orally with omeprazole (30 mg/kg, for 5 days) (Table 5). GEO analysis showed that VEGF gene expression was upregulated in the rat livers after oral omeprazole treatment.

2.6  Effect of PPI on VEGFA expression using human cell lines

The influence of PPI on VEGF gene expression was evaluated using human vascular endothelial cells (HUVEC). Exposure of PPIs (omeprazole, rabeprazole, lansoprazole, pantoprazole, and esomeprazole; 100 μM) increased cell proliferation significantly in HUVEC, as did the exposure of VEGF. However, there were no significant increases with exposure of famotidine. Thus, the effect of PPI on VEGF-A mRNA expression was then evaluated using LS174T cells. VEGF-A mRNA expression was significantly increased by PPI exposure in LS174T cells. However, there was no

| Group            | Hypertension without bevacizumab (%) | Hypertension with bevacizumab (%) | ROR | 95% CI       | p-value |
|------------------|--------------------------------------|----------------------------------|-----|--------------|---------|
| Total            | 83559/3695466 (2.26)                 | 1520/28288 (5.37)                | 2.45| 2.33-2.59    | <0.001  |
| Stratified by gender |                                       |                                   |     |              |         |
| Male             | 28076/1274753 (2.2)                  | 414/11466 (3.61)                 | 1.66| 1.51-1.84    | <0.001  |
| Female           | 51603/2090097 (2.47)                 | 776/13658 (5.68)                 | 2.38| 2.21-2.56    | <0.001  |
| Stratified by age (y) |                             |                                   |     |              |         |
| <40              | 8342/527869 (1.58)                  | 60/1232 (4.87)                  | 3.19| 2.46-4.14    | <0.001  |
| 40–4             | 7758/321558 (2.41)                  | 104/1998 (5.21)                 | 2.22| 1.82-2.71    | <0.001  |
| 50–59            | 13054/470547 (2.77)                 | 214/4062 (5.27)                 | 1.95| 1.7-2.24     | <0.001  |
| 60–69            | 14250/472096 (3.02)                 | 299/5476 (5.46)                 | 1.86| 1.65-2.09    | <0.001  |
| 70–100           | 15478/529240 (2.92)                 | 248/4663 (5.32)                 | 1.86| 1.64-2.12    | <0.001  |
In this study, we identified drugs that reduced the occurrence of hypertension in patients treated with bevacizumab and then investigated whether these drugs could reduce the efficacy of bevacizumab. We used FAERS to identify that among patients treated with bevacizumab, there were fewer reports of hypertension in patients taking omeprazole. However, the other PPIs did not show an association with the reduction in the occurrence of hypertension in patients treated with bevacizumab. This may be due to the long period of time since omeprazole was approved and the high number of reports compared with the number of adverse event reports for other PPIs in the FAERS database. For large databases such as FAERS, it is difficult to achieve unsupervised collection results and some data may be inaccurate. Furthermore, there are no data on individual patient characteristics. Therefore, we retrospectively investigated the medical records of patients in our hospital.

In the clinical records study, we examined the association between the use of PPIs and response rates. There was a 25% (though not statistically significant) reduction in the ORR and 21% reduction in the disease control rate in patients using PPIs. Thus, there was a reduction in the response to bevacizumab combination chemotherapy. There were no significant differences between the two groups for factors such as stage, PS, or combination regimen.

Although FAERS analysis showed a reduced rate of bevacizumab-induced hypertension in patients using PPIs, but there was no significant reduction in the chart reviews. This may be because many patients in our hospital had developed hypertension before bevacizumab was administered and were already satisfactorily treated with antihypertensive drugs. Furthermore, the PPI group might have had lower numbers of hypertensive patients, which may have prevented them from achieving significant results. This study suggests that PPI not only reduces the incidence of hypertension in patients treated with bevacizumab but also reduces the efficacy of this drug. However, this study did not examine the duration of PPI treatment.
dosing, and further investigation is needed to determine the extent to which PPI-use influences the effects and adverse events of bevacizumab.

We investigated the molecular mechanisms by which the combination of PPI and bevacizumab was found to be associated with poor antitumor effect. We analyzed the GEO databases and found that PPI induces VEGF gene expression. It has also been previously suggested that drugs that inhibit VEGF expression reduce VEGF-induced angiogenesis. This suggests that PPI might reduce the therapeutic effect of bevacizumab by inducing the expression of VEGF.

Therefore, we then investigated the effects of PPIs on tumor growth and angiogenesis using the human cell lines. We found that PPIs promoted cell proliferation in the vascular endothelial cell line HUVEC. The inhibition of angiogenesis was related to the mechanism of tumor growth inhibition by bevacizumab, suggesting that the promotion of angiogenesis by PPIs in tumor tissues might have led to a lower response rate in patients using PPI. Next, using the colon cancer cell line LS174T, we revealed that PPIs promoted the expression of the VEGF mRNA expression in the tumor cells. These results indicated that PPI induced VEGF expression in tumor cells might have promoted the angiogenesis and cancer cell growth. This could be the mechanism that led to the reduced therapeutic efficacy of bevacizumab in the medical records study. This effect may also vary according to cancer type and should be further investigated for other types of cancer. However, it has been reported that PPIs have an enhanced antitumor effect in pancreatic cancer. Therefore, for anti-tumor agents other than bevacizumab, PPIs may have a synergistic effect by mechanisms other than VEGF.

There are possible limitations in this study. FAERS analysis includes reporting bias and unmeasured confounding factors. Furthermore, not all adverse events observed in clinical practice are included in the database. Under reporting or selective reporting might be included. Because the FAERS database contains missing data, incorrect drug names, and duplicate data, we removed or corrected such data before the analysis. The FAERS analysis showed that some variables were also limited. We also did not consider race, duration of treatment, drug dosage, or co-administration of other medications. Although hypertension may have occurred prior to treatment as an underlying condition, the treatment time and the other medications were not listed in the FAERS database. While these aforementioned factors might affect the results, the use of self-reporting systems can be useful in detecting potential drug signals. Moreover this was a single-center study and was limited to a specific type of cancer, thus, a multicenter study with a larger cohort is required. Additionally, the relationship between the PPI and the treatment effect of bevacizumab has not been examined because not enough cases have been collected for evaluation. Therefore, further studies are needed to conclude the possibility of PPIs decreasing the therapeutic effect of bevacizumab. Furthermore, further studies, including multicenter and randomized trials, may be considered.

However, we should never dismiss the use of PPIs. PPIs are very important in many diseases such as gastric ulcers and reflux esophagitis. However, the long-term use of PPIs may be a risk factor for stomach cancer and shorter prognosis for lung cancer patients receiving immune checkpoint inhibitors. Thus, although PPIs are currently effective in gastric conditions and are frequently used, they may not be used properly. It may be necessary to avoid long-term administration of PPI which should be administered to only those who truly require it.
In conclusion, the use of PPIs might reduce the antitumor activity of bevacizumab in patients receiving bevacizumab.

4 | MATERIALS AND METHODS

4.1 | Analysis of the FAERS database

The FAERS data sets for the third quarter of 2010 to the second quarter of 2015 were obtained from the FDA website (https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm). Following the FDA’s recommended method, we used the most recent case numbers to exclude duplicate reports (out of a total of 4331802 reports) and analyzed the remaining 3724555 reports. The definition of hypertension was based on the 10 terms from the Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries [Hypertension] (SMQ code: 20000147), published in MedDRA/J ver 19.0, by the International Council for Harmonisation.

FAERS reports were classified into four groups: (a) received bevacizumab and reported hypertension, (b) received bevacizumab but did not report hypertension, (c) did not receive bevacizumab but reported hypertension, and (d) did not receive bevacizumab and did not report hypertension. The ROR was used to signal detection and was calculated using the following equation.16,33

Calculation for ROR: \( \text{ROR} = \frac{a/b}{c/d} \).

\[ 95\%\text{CI} = \exp(\log(\text{OR}) \pm 1.96 \text{SEM}) \]

Letters a, b, c, and d indicate the number of individuals in each group. If the lower limit of the 95% CI was >1, it was assumed that there was a relationship between the drug use of interest and hypertension report. Conversely, if the upper limit of the 95% CI <1, we assumed that there was an association between the drug use of interest and reduced hypertension report.

4.2 | Analysis of the medical chart review

In this retrospective study, we investigated patients’ medical records. This data was collected from the medical records of patients who visited our hospital. Patients aged ≥18 years who were diagnosed with colorectal cancer at The Tokushima University Hospital between January 2010 and December 2015 and were treated with bevacizumab combination XELOX, or mFOLFOX6 for the first time, and patients with evaluated lesions using Response Evaluation Criteria in Solid Tumors (RECIST) were included. Patients who were treated with <1 course of bevacizumab, failed to follow-up, and had missing values were excluded. This study was approved by the Ethics Committee of Tokushima University Hospital (Approval Number: 2962-1).

The following data were extracted from patient charts: age at diagnosis, sex, cancer type, stage at diagnosis (using the 6th edition AJCC system), Eastern Cooperative Oncology Group PS, bevacizumab dose, treatment duration, blood pressure, and PPI-use. Patients were considered to have received concomitant PPIs if they had been prescribed PPIs continuously during the bevacizumab treatment period. Blood pressure was measured by the nurse prior to administration of bevacizumab for each cycle. The event of hypertension in patients receiving bevacizumab was defined according to the Common Terminology Criteria for Adverse Events v 4.0 (CTCAE v 4.0): an increase in blood pressure of <20 mmHg, an increase in blood pressure to ≥150/100 mmHg, or hypertension requiring initiation or increase in therapeutic medication. Those who were taking antihypertensive medication...
before bevacizumab treatment were considered “taking antihypertensive medication” and those who started antihypertensive medication after bevacizumab treatment were considered “not taking antihypertensive medication.” The stage of cancer was extracted from the medical records, and relapse cases were considered as stage IV.

Treatment response was assessed according to RECIST version 1.0 as follows: CR, PR, SD, and PD. The primary endpoint was assessed using the ORR, which is the number of patients achieving CR or PR divided by the number of patients evaluated. Disease control was defined as the number of patients achieving CR, PR, and SD divided by the number of patients assessed.

### 4.3 Analysis of the GEO and KEGG PATHWAY databases

Microarray gene expression data were obtained from the National Center for Biotechnology Information (NCBI) GEO database (http://www.ncbi.nlm.nih.gov/geo/) (accession number GSE59927). We analyzed expression data using samples analyzed in the livers of rats receiving oral omeprazole (30 mg/kg, once daily/5 days) or vehicle (carboxymethylcellulose), focusing on genes involved in the VEGF signaling pathway extracted from the KEGG PATHWAY database (entry number: MAP04370 http://www.genome.jp/dbget-bin/www_bget?pathway:map04370). The expression levels of each gene were shown in relation to controls by inverting the log2-transformed microarray data to the original scale.

We chose a rat model and not a human model for this analysis because in reality, the patients were treated with a number of drugs in combination. Thus, it was ethically difficult to administer PPIs alone to humans, and to obtain tissue samples for comparison before and after PPI administration. Therefore, to exclude the effects of concomitant drugs, in vivo experiments were needed to investigate the effects of these drugs.

### 4.4 Real-time PCR and cell proliferation assay

The LS174T (human colon cancer cells) and HUVEC were cultured in α-MEM supplemented with 5% fetal bovine serum and 10 mg/mL of 1% (v/v) penicillin streptomycin (Sigma Aldrich, MO, USA). All cells were incubated at 37°C in a humidified atmosphere containing 5% (v/v) CO₂. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H tetrazolium bromide (MTT) was then added, and the cell proliferation rate was measured.

LS174T cells were used to investigate gene expression. Cells were seeded in 6-well plates and incubated for 24 hours, then exposed to PPI: esomeprazole, pantoprazole, omeprazole, (10 μM), famotidine (100 μM), CoCl₂ (100 μM), and DMSO (0.1% v/v) for 24 hours. Total RNA was extracted from cells using ISOGEN (NIPPON GENE) according to the manufacturer's protocol. Total RNA was reverse transcribed to cDNA using Prime Script™ RT reagent Kit with gDNA Eraser (TaKaRa). The cDNA product was used as a template for Polymerase Chain Reaction (PCR) amplification in a total volume of 10 μl, and the PCR condition were as follows: 95°C for 2 minutes, followed by 40 cycles at 95°C for 5 seconds, 60°C for 30 seconds, and 95°C for 5 seconds. Reactions were conducted on a CFX96 Real-time PCR Detection System (Bio-Rad). All data were analyzed with the CFX Manager Software (Bio-Rad). The data were analyzed using the delta cycle threshold method and calculated based on the Cq values; the expression of each gene was normalized to 36B4. Gene-specific primer pairs were used: h-VEGFA: (F) 5'-AGGAGGAGGGCAAGAATCATC-3', (R) 5'-ATGGTCCGATTCTGAT-3'; 36B4: (F) 5'-GCTCCAAGCAGATCGAGC-3', (R) 5'-CCGGATGTGAGGCAGCAGCAG-3'.

### 4.5 Statistical analysis

For FAERS analysis, Microsoft Access 2013 was used for the FAERS database construction and R ver 3.2.1 (R Foundation for Statistical Computing, Vienna, Austria) was used for statistical analysis using the Fisher’s exact test. For the retrospective chart review, the Mann-Whitney U-test was used as the distribution was not normal. Differences between categorical values were estimated using the chi-square or Fisher’s exact test for comparisons with cells <5. Data obtained from the pathway analysis of RT-PCR experiments were performed using the Dunnett’s test. All recorded P values were two-sided, and P values <0.05 were considered significant.

The continuous variable case records are shown as mean ± standard deviation. The demographic characteristics were evaluated with descriptive statistics. Student’s t test with Welch’s correction was used when the data distribution was normal, and the Mann-Whitney U-test was used when the distribution was not normal.

### ACKNOWLEDGMENTS

The authors thank the support received from the Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan and are grateful to Saito H and Moriguchi H for helpful discussions. Additionally, the
authors also thank Editage (www.editage.com) for English language editing.

CONFICT OF INTEREST
The authors have no conflicts of interest directly relevant to the content of this article.

AUTHOR CONTRIBUTIONS
YZ is the principal investigator and guarantor of the paper, had full access to all the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis. KY designed the research and drafted the manuscript. MM, TN, YI, MG, MC, KS, SI, KS, NO, HH, YH, YI, HY, and KI contributed to the acquisition, analysis, or interpretation of data and critically reviewed and revised the article for important intellectual content. All authors approved the final manuscript and decided to submit the article for publication.

ORCID
Kenta Yagi https://orcid.org/0000-0003-0869-5786
Naoto Okada https://orcid.org/0000-0003-2476-9191

REFERENCES
1. Ahmadizar F, Onland-Moret NC, de Boer A, Liu G, Maitland-van der Zee AH. Efficacy and safety assessment of the addition of bevacizumab to adjuvant therapy agents in cancer patients: A systematic review and meta-analysis of randomized controlled trials. PLoS One. 2015;10(9):e0136324.
2. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREET study. J Clin Oncol. 2008;26(21):3523–3529.
3. Corr BR, Breed C, Sheeder J, Weisdack S, Behbahkt K. Bevacizumab induced hypertension in gynecologic cancer: does it resolve after completion of therapy? Gynecol Oncol Rep. 2016;17:65–68.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.
5. Miles D, Cameron D, Bondarenko I, et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. European Journal of Cancer Elsevier Ltd. 2017;70:146–155.
6. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol. 2013;14:29–37.
7. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Corman TM. Vascular endothelial growth factor Receptor 2 (Vegfr2) controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54(3):652–658.
8. Dionisio de Sousa JJ, Ferreira J, Rodrigues J, et al. Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer. ESMO Open. 2016;1(3):e000045.
9. Plummer C, Michael A, Shaikh G, et al. Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. Br J Cancer Springer. US. 2019;121:109–116.
10. Zhang BO, Fang C, Deng D, Xia L. Research progress on common adverse events caused by targeted therapy for colorectal cancer (Review). Oncol Lett. 2018;16:27–33.
11. Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies—focus on hypertension and arterial thrombotic events. J Am Soc Hypertens Elsevier Inc. 2018;12(6):409–425.
12. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.
13. Horinouchi Y, Sakurada T, Nakamura T, et al. Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer. Yakugaku Zasshi. 2011;131(8):1251–1257.
14. Österlund P, Soever LM, Isonieminen H, Poussa T, Alanko T, Bono P. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer. 2011;104(4):599–604.
15. Tahover E, Uziely B, Salah A, Temper M, Perez T, Hubert A. Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol. 2013;30(1):327.
16. De Stefano A, Carlonagno C, Pepe S, Bianco R, De Placidio S. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol. 2011;68(5):1207–1213.
17. Nagashima T, Shirakawa H, Nakagawa T, Kaneko S. Prevention of antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism. Sci Rep. 2016;6:26375.
18. Zhao S, Nishimura T, Chen Y, et al. Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med. 2013;5(206):206ra140.
19. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–210.
20. Zamami Y, Niimura T, Koyama T, et al. Search for therapeutic agents for cardiac arrest using a drug discovery tool and large-scale medical information database. Front Pharmacol. 2019;10: https://doi.org/10.3389/fphar.2019.01257.
21. Izawa-Ishizawa Y, Imanishi M, Zamami Y, et al. Development of a novel aortic dissection mouse model and evaluation of drug efficacy using in-vivo assays and database analyses. J Hypertens. 2019;37(1):73–83.
22. Okada N, Niimura T, Zamami Y, et al. Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and bcr-abl inhibitor use by using an adverse drug event reporting database. Cancer Med. 2019;8(1):174–181.
23. Dithmer M, Fuchs S, Shi Y, et al. Fucoidan reduces secretion and expression of vascular endothelial growth factor in the retinal pigment epithelium and reduces angiogenesis in vitro. PLoS One. 2014;9.
24. Zhao M, Yu Z, Li Z, Tang J, Lai X, Liu L. Expression of angiogenic growth factors VEGF, bFGF and ANG1 in colon cancer after bevacizumab treatment in vitro: a potential self-regulating mechanism. Oncol Rep. 2017;37:601–607.
25. Haibe Y, Kreidieh M, El Hajj H, et al. Resistance mechanisms to anti-angiogenic therapies in cancer. Frontier Oncol. 2020;10.

26. Tozzi M, Sørensen CE, Magni L, et al. Proton pump inhibitors reduce pancreatic adenocarcinoma progression by selectively targeting H+, K+-ATPases in pancreatic cancer and stellate cells. Cancers. 2020;12:1-22.

27. Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7(10):e017739.

28. Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: A population-based study. Gut. 2018;67(1):28-35.

29. Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and poplar trials. Ann Oncol. 2020;31(4):525-531.

30. Diao X. Antibiotics and proton pump inhibitors suppress the efficacy of immunotherapy against non-small cell lung cancer. Thorac Cancer. 2020;11(7):1763-1764.

31. Reid M, Keniston A, Heller JC, Miller M, Medvedev S, Albert RK. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med. 2012;7:421-425.

32. Naunton M, Peterson GM, Deeks LS, Young H, Kosari S. We have had a gutful: The need for deprescribing proton pump inhibitors. J Clin Pharm Ther. 2018;43:65–72.

33. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3-10.

How to cite this article: Yagi K, Mitstui M, Zamami Y, et al. Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect. Cancer Med. 2021;10:164–172. https://doi.org/10.1002/cam4.3587